Research programme: immune tolerance technology - BioMarin Pharmaceutical
Latest Information Update: 10 Mar 2010
At a glance
- Originator BioMarin Pharmaceutical
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 07 Jul 2006 Preclinical trials in Autoimmune disorders in USA (unspecified route)